Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Enanta Pharmaceuticals (ENTA) over the last 9 years, with Q3 2025 value amounting to $2.4 million.

  • Enanta Pharmaceuticals' Interest Expenses fell 751.65% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 2978.98%. This contributed to the annual value of $7.7 million for FY2025, which is 2978.98% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Interest Expenses is $2.4 million, which was down 751.65% from $1.6 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Interest Expenses' 5-year high stood at $3.4 million during Q4 2023, with a 5-year trough of $1.6 million in Q2 2025.
  • For the 3-year period, Enanta Pharmaceuticals' Interest Expenses averaged around $2.4 million, with its median value being $2.4 million (2024).
  • Examining YoY changes over the last 5 years, Enanta Pharmaceuticals' Interest Expenses showed a top increase of 1792.69% in 2024 and a maximum decrease of 4298.17% in 2024.
  • Enanta Pharmaceuticals' Interest Expenses (Quarter) stood at $3.4 million in 2023, then tumbled by 42.98% to $2.0 million in 2024, then grew by 21.66% to $2.4 million in 2025.
  • Its Interest Expenses was $2.4 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.7 million in Q1 2025.